Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment

Onkologie

Volumn 31, Issue 8-9, 2008, Pages 447-453

  Meier, Carl Richard ^a,i   Illiger, Hans Jochen ^b   Steder, Martin ^c   Janssen, Jan ^b   Deertz, Holger ^d   Braun, Manfred ^e   Oeney, Hueseyin Taylan ^f   Deuss, Burkhard ^g   Küchler, Thomas ^h   Rotermund, Susanne ^a  

^a KLINIKUM BREMEN MITTE   (Germany)

^b KLINIKUM ESSLINGEN   (Germany)

^c PIUS HOSPITAL   (Germany)

^d Evangelisches Krankenhaus Oberhausen   (Germany)

^e Klinikum Bremen Nord   (Germany)

^f Klinikum Links der Weser   (Germany)

^g CLINASSESS GMBH   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Crossover studies; Docetaxel; Metastatic breast cancer; Quality of life; Vinorelbine

Indexed keywords

ANTHRACYCLINE; DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; DIARRHEA; DRUG RESPONSE; EFFUSION; FATIGUE; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERSENSITIVITY; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYOPATHY; NAIL DISEASE; NEUTROPENIA; PAIN; QUALITY OF LIFE; SCORING SYSTEM; SKIN TOXICITY; STOMATITIS; THERAPY DELAY; TREATMENT FAILURE;

ADULT; AGED; ANTHRACYCLINES; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME; VINBLASTINE;

EID: 52249121413     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000140453     Document Type: Article

References (31)

1. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61.
2. Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gerstner JB, Pfeifle DM, Marschke RF, Jr., Long HJ, McCormack GW, Foley JF: Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. Am J Clin Oncol 1989;12:474-480.
3. Joensuu H, Holli K, Heikkinen M, Suonio E, Aro AR, Hietanen P, Huovinen R: Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998;16:3720-3730.
4. Heidemann E, Stoeger H, Souchon R, Hirschmann WD, Bodenstein H, Oberhoff C, Fischer JT, Schulze M, Clemens M, Andreesen R, Mahlke M, Konig M, Scharl A, Fehnle K, Kaufmann M: Is first-line single-agent mitoxantrone in the treatment of highrisk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 2002;13:1717-1729.
5. Neidhart JA, Gochnour D, Roach R, Hoth D, Young D: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 1986;4:672-677.
6. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205.
7. Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhonen S: Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 1994;12:1639-1647.
8. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M, et al.: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-1424.
9. Ravdin PM, Burris HA, 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-2885.
10. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-2894.
11. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35:1194-1201.
12. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, Ambrosini G: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994;12:2094-2101.
13. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, Demaille A: Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5:423-426.
14. Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995;13:2567-2574.
15. Nistico C, Garufi C, Milella M, Vaccaro A, D'Ottavio AM, Fabi A, Pace A, Bove L, Tropea F, Marsella A, Izzo F, D'Attino RM, Ferraresi V, De Marco S, Terzoli E: Weekly schedule of vinorelbine in pretreated breast cancer patients. Breast Cancer Res Treat 2000;59:223-229.
16. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA: Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395-1400.
17. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1219.
18. Hainsworth JD, Burris HA 3rd, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19:3500-3505.
19. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J: A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15:1358-1365.
20. Warm M, Nawroth F, Ohlinger R, Valter M, Pantke E, Mallmann P, Harbeck N, Kates R, Thomas A: Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer. Onkologie 2007;30:436-441.
21. European Network of GCP Auditors and other GCP Experts: Optional Guideline for Good Clinical Practice Compliance and Quality Systems Auditing (date 21 August 1997): in conformity with: Note for Guidance on GCP CPMP/ICH/135/95 (ICH GCP). 1998.
22. Anonymous: World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Jama 1997;277:925-926.
23. Lehmacher W, Wassmer G: Adaptive sample size calculations in group sequential trials. Biometrics 1999;55:1286-1290.
24. Hamilton A, Hortobagyi G: Chemotherapy: what progress in the last 5 years? J Clin Oncol 2005;23:1760-1775.
25. Stewart DJ, Evans WK, Shepherd FA, Wilson KS, Pritchard KI, Trudeau ME, Wilson JJ, Martz K: Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 1997;15:1897-1905.
26. Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ: Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002;13:197-207.
27. Inuyama Y, Kataura A, Togawa K, Saijo S, Satake B, Takeoda S, Konno A, Ebihara S, Sasaki Y, Kida A, Kanzaki J, Ichikawa G, Kono N, Moriyama H, Kamata S, Miyake H, Sakai M, Horiuchi M, Kubota A, Tsukuda M, Matsuura H, Baba S, Saito H, Matsunaga T, Taguchi T, et al.: [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer]. Gan To Kagaku Ryoho 1999;26:107-116.
28. Krol J, Paepke S, Jacobs VR, Paepke D, Euler U, Kiechle M, Harbeck N: G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients. Onkologie 2006;29:171-178.
29. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D, Sutherland H: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988;6:1377-1387.
30. McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB: Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995;13:858-868.
31. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN: Is breast cancer survival improving? Cancer 2004;100:44-52.